CIP2A在肝癌组织中的表达及其临床意义

CIP2A expression in hepatocellular carcinoma and its clinicopathological significance

目的探讨CIP2A在肝细胞癌中的表达及其与肝癌临床病理特征的关系。方法采用免疫组化法分析CIP2A蛋白在肝癌组织、癌旁肝组织以及正常肝脏组织中的表达分布;采用RT-PCR法检测肝癌组织及其相对应的癌旁肝组织中CIP2A mRNA的转录水平,统计分析CIP2A mRNA的转录水平与肝癌临床病理特征之间的关系。结果 CIP2A阳性表达主要定位于细胞胞质,肝癌组织中阳性表达率为71.7%(43/60);相对应的癌旁肝组织则较少见CIP2A蛋白阳性表达,其阳性率为23.3%(14/60),且阳性染色分布散在稀疏;正常肝组织中未见CIP2A蛋白阳性表达。肝癌组织中CIP2A mRNA的转录水平显著高于其相对应的癌旁肝组织(P<0.05)。CIP2A mRNA转录水平与肝癌直径、肝癌组织病理分化、临床TNM分期以及是否合并肝癌转移(门静脉癌栓浸润以及肝内转移)等临床病理特征显著相关(P<0.05)。结论 CIP2A在肝癌组织中高表达,且与肝癌的恶性临床病理特征密切相关;CIP2A可能成为潜在的肝癌分子标志物或治疗靶点。

Objective To investigate the expression of cancerous inhibitor of protein phosphatase 2A（CIP2A） in human hepatocellular carcinoma and its relation with the clinicopathologic characteristics of the carcinoma.Methods Hepatocellular carcinoma tissues and the corresponding non-tumorous tissues from 60 patients with hepatocellular carcinoma were analyzed for CIP2A expression using immunohistochemical staining and RT-PCR.By combining with clinical features of these patients,the relationship between CIP2A mRNA transcription level and clinicopathologic characteristics was studied with statistical analysis.Results CIP2A was expressed in the cell cytoplasm.Immunohistochemical staining showed that the positive expression rate of CIP2A protein was higher in hepatocellular carcinoma tissues than in their corresponding non-tumor tissues（71.7% vs.23.3%,P〈0.05）,and there was no positive staining of CIP2A protein in normal liver tissues from 9 cases of paraffin section.CIP2A mRNA transcription level in hepatocellular carcinoma tissues was significantly higher than that in the corresponding non-tumor tissues（P〈0.05）.The clinicopathologic evaluation revealed that the higher transcription level of CIP2A mRNA in hepatocellular carcinoma tissues was correlated with bigger tumor size,poorly-differentiated histologic grades,later clinical TNM stage and metastasis（portal invasion and intrahepatic metastasis） of hepatocellular carcinoma.Conclusion CIP2A is overexpressed in hepatocellular carcinoma and closely correlated with the malignant clinicopathologic features of the carcinoma.CIP2A may act as a novel biomarker and can be a therapeutic target in patients with hepatocellular carcinoma.